{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:11:44Z","timestamp":1794409904587,"version":"4.9.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the financial support of the Clinical Medicine and Pharmacy Research Center, Forth Military Medical University","award":["LHJJ2024-YX21"],"award-info":[{"award-number":["LHJJ2024-YX21"]}]},{"name":"the financial support of the Clinical Medicine and Pharmacy Research Center, Forth Military Medical University","award":["LHJJ2024-YX03"],"award-info":[{"award-number":["LHJJ2024-YX03"]}]},{"name":"the innovation capacity support program of Shaanxi province","award":["2023-CX-TD-76"],"award-info":[{"award-number":["2023-CX-TD-76"]}]},{"name":"the health research and innovation capacity enhancement program of Shaanxi province","award":["2023PT-10"],"award-info":[{"award-number":["2023PT-10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatohepatitis (MASH) has emerged as the primary contributor to the increasing incidence and mortality rates linked to cirrhosis and hepatocellular carcinoma globally, while the availability of clinical treatment drugs remains severely limited. Ecliptasaponin A (EA), naturally isolated from Ecliptae Herba, possesses multiple biological activities. However, the effects of EA on MASH remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to explore the roles of EA in MASH and its engaged mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two established NASH animal models, non-obese MASH induced by methionine-choline-deficient (MCD) dietary administration and obese MASH developed through high-fat\/high-cholesterol (HFHC) feeding were employed to assess EA's therapeutic effects in vivo. RNA-seq analysis was conducted to uncover EA's molecular mechanisms. Complementary in vitro investigations utilized LPS-treated BMDMs and THP1 cells, and TGF-\u03b21-activated LX-2 hepatic stellate cells to systematically examine EA's cellular-level impacts and regulatory pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Oral administration of EA demonstrated dose-responsive therapeutic effects against MCD\/HFHC-induced MASH. The compound effectively attenuated hepatic steatosis, inflammatory responses, and fibrotic progression in experimental models through dual modulation of NLRP3 and YAP signaling pathways. Mechanistic studies revealed EA specifically suppressed NLRP3 inflammasome activation in BMDMs without affecting AIM2 or NLRC4 inflammasomes, effectively blocking cytokine secretion, pyroptotic cell death, caspase-1 activation, and inflammasome complex formation. Molecular interactions analysis confirmed EA directly binds to NLRP3, disrupting inflammasome assembly. In LX-2 cells, EA suppressed TGF-\u03b21-induced COL1A1 and \u03b1-SMA expression while reducing YAP protein levels. Genetic silencing or pharmacological inhibition of YAP failed to potentiate EA's anti-fibrotic effects on \u03b1-SMA suppression, Collagen I expression, or YAP-regulated gene transcription. Molecular docking and SPR showed that EZ could directly bind to NLRP3 and YAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings reveal novel perspectives on the natural compound Ecliptasaponin A, demonstrating its dual-targeting capability against both NLRP3 inflammasome activation and YAP signaling cascades. This discovery highlights its potential as a promising therapeutic agent for mitigating MASH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-025-01321-9","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:34:12Z","timestamp":1768293252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ecliptasaponin A alleviates inflammation and fibrosis in experimental MASH mice via targeting the NLRP3 inflammasome and YAP signaling pathway"],"prefix":"10.1186","volume":"21","author":[{"given":"Kai","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingru","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"1321_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100863","author":"R Bauer","year":"2020","unstructured":"Bauer R, Rauch I. The NAIP\/NLRC4 inflammasome in infection and pathology. Mol Aspects Med. 2020. https:\/\/doi.org\/10.1016\/j.mam.2020.100863.","journal-title":"Mol Aspects Med"},{"key":"1321_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091332","author":"W Chamulitrat","year":"2020","unstructured":"Chamulitrat W, Jansakun C, Li HL, Liebisch G. Rescue of hepatic phospholipid remodeling defect in iPLA2\u03b2-null mice attenuates obese but not non-obese fatty liver. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10091332.","journal-title":"Biomolecules"},{"key":"1321_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-pathol-030420-105050","volume":"16","author":"JH Driskill","year":"2021","unstructured":"Driskill JH, Pan DJ. The hippo pathway in liver homeostasis and pathophysiology. Ann Rev Pathol Mech Dis. 2021;16:299\u2013322.","journal-title":"Ann Rev Pathol Mech Dis"},{"key":"1321_CR4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1053\/j.gastro.2017.12.022","volume":"154","author":"K Du","year":"2018","unstructured":"Du K, Hyun J, Premont RT, Choi SS, Michelotti GA, Swiderska-Syn M, et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology. 2018;154:1465-1479.e1413.","journal-title":"Gastroenterology"},{"key":"1321_CR5","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1097\/HEP.0000000000000326","volume":"77","author":"K Du","year":"2023","unstructured":"Du K, Maeso-D\u00edaz R, Oh SH, Wang E, Chen TY, Pan CSP, et al. Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology. 2023;77:1998\u20132015.","journal-title":"Hepatology"},{"key":"1321_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-G\u00f3mez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"1321_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","volume":"21","author":"G Feng","year":"2024","unstructured":"Feng G, Valenti L, Wong VWS, Fouad YM, Yilmaz Y, Kim W, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2024;21:46\u201356.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1321_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"1321_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-025-01090-5","author":"K Gao","year":"2025","unstructured":"Gao K, Zhang W, Xu D, Zhao MN, Tao XR, Lu YY, et al. Chikusetsusaponin IVa targeted YAP as an inhibitor to attenuate liver fibrosis and hepatic stellate cell activation. Chin Med. 2025. https:\/\/doi.org\/10.1186\/s13020-025-01090-5.","journal-title":"Chin Med"},{"key":"1321_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","volume":"74","author":"S Gaul","year":"2021","unstructured":"Gaul S, Leszczynska A, Alegre F, Kaufmann B, Johnson CD, Adams LA, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol. 2021;74:156\u201367.","journal-title":"J Hepatol"},{"key":"1321_CR11","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1016\/j.jmb.2015.04.015","volume":"427","author":"K Grannas","year":"2015","unstructured":"Grannas K, Arngarden L, L\u00f6nn P, Mazurkiewicz M, Blokzij A, Zieba A, et al. Crosstalk between Hippo and TGF\u03b2: Subcellular Localization of YAP\/TAZ\/Smad Complexes. J Mol Biol. 2015;427:3407\u201315.","journal-title":"J Mol Biol"},{"key":"1321_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202300529","author":"YT Hao","year":"2024","unstructured":"Hao YT, Feng DL, Ye HR, Liao WZ. Nobiletin alleviated epithelial-mesenchymal transition of hepatocytes in liver fibrosis based on autophagy-Hippo\/YAP pathway. Mol Nutr Food Res. 2024. https:\/\/doi.org\/10.1002\/mnfr.202300529.","journal-title":"Mol Nutr Food Res"},{"key":"1321_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","volume":"41","author":"Y He","year":"2016","unstructured":"He Y, Hara H, N\u00fa\u00f1ez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41:1012\u201321.","journal-title":"Trends Biochem Sci"},{"key":"1321_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23112807","author":"GU Hong","year":"2018","unstructured":"Hong GU, Lee JY, Kang H, Kim TY, Park JY, Hong EY, et al. Inhibition of osteoarthritis-related molecules by Isomucronulatol 7-O-\u03b2-D-glucoside and Ecliptasaponin A in IL-1\u03b2-stimulated chondrosarcoma cell model. Molecules. 2018. https:\/\/doi.org\/10.3390\/molecules23112807.","journal-title":"Molecules"},{"key":"1321_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature07725","volume":"458","author":"V Hornung","year":"2009","unstructured":"Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514-U516.","journal-title":"Nature"},{"key":"1321_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/cmi.2015.95","volume":"13","author":"EK Jo","year":"2016","unstructured":"Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13:148\u201359.","journal-title":"Cell Mol Immunol"},{"key":"1321_CR17","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1126\/science.1240248","volume":"341","author":"N Kayagaki","year":"2013","unstructured":"Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science. 2013;341:1246\u20139.","journal-title":"Science"},{"key":"1321_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024;84:729\u201335.","journal-title":"Drugs"},{"key":"1321_CR19","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/hep.31167","volume":"72","author":"S Kumar","year":"2020","unstructured":"Kumar S, Verma AK, Rani R, Sharma A, Wang J, Shah SA, et al. Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis. Hepatology. 2020;72:1586\u2013604.","journal-title":"Hepatology"},{"key":"1321_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","volume":"157","author":"M Lamkanfi","year":"2014","unstructured":"Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013\u201322.","journal-title":"Cell"},{"key":"1321_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31749","volume":"74","author":"T Lan","year":"2021","unstructured":"Lan T, Yu Y, Zhang J, Li HN, Weng QQ, Jiang S, et al. Cordycepin ameliorates nonalcoholic steatohepatitis by activation of the AMP-activated protein kinase signaling pathway. Hepatology. 2021;74:686\u2013703.","journal-title":"Hepatology"},{"key":"1321_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s11626-023-00803-0","volume":"59","author":"XM Li","year":"2023","unstructured":"Li XM, Dong WH, Yang YL, Ren SJ, Wang XY, Zou MN, et al. Ecliptasaponin A attenuates renal fibrosis by regulating the extracellular matrix of renal tubular cells. In Vitro Cell Dev Biol Anim. 2023;59:684\u201396.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"1321_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/HEP.0000000000000933","volume":"81","author":"MP Moore","year":"2025","unstructured":"Moore MP, Wang X, Kennelly JP, Shi H, Ishino Y, Kano K, et al. Low MBOAT7 expression, a genetic risk for MASH, promotes a profibrotic pathway involving hepatocyte TAZ upregulation. Hepatology. 2025;81:576\u201390.","journal-title":"Hepatology"},{"key":"1321_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","volume":"20","author":"IM Moya","year":"2019","unstructured":"Moya IM, Halder G. Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211\u201326.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1321_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66:1037\u201346.","journal-title":"J Hepatol"},{"key":"1321_CR26","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","volume":"38","author":"R Mu\u00f1oz-Planillo","year":"2013","unstructured":"Mu\u00f1oz-Planillo R, Kuffa P, Mart\u00ednez-Col\u00f3n G, Smith BL, Rajendiran TM, N\u00fa\u00f1ez G. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38:1142\u201353.","journal-title":"Immunity"},{"key":"1321_CR27","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605\u201316.","journal-title":"Hepatology"},{"key":"1321_CR28","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"1321_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","volume":"16","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377\u201386.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1321_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1321_CR31","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175\u201383.","journal-title":"JAMA"},{"key":"1321_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02305","author":"N Song","year":"2018","unstructured":"Song N, Li T. Regulation of NLRP3 inflammasome by phosphorylation. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.02305.","journal-title":"Front Immunol"},{"key":"1321_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/JME-18-0069","volume":"61","author":"S Song","year":"2018","unstructured":"Song S, Qiu DJ, Luo FW, Wei JY, Wu M, Wu HJ, et al. Knockdown of NLRP3 alleviates high glucose or TGFB1-induced EMT in human renal tubular cells. J Mol Endocrinol. 2018;61:101\u201313.","journal-title":"J Mol Endocrinol"},{"key":"1321_CR34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jhep.2012.03.035","volume":"57","author":"G Szabo","year":"2012","unstructured":"Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57:642\u201354.","journal-title":"J Hepatol"},{"key":"1321_CR35","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1681\/ASN.2015050499","volume":"27","author":"SG Szeto","year":"2016","unstructured":"Szeto SG, Narimatsu M, Lu ML, He XL, Sidiqi AM, Tolosa MF, et al. YAP\/TAZ are mechanoregulators of TGF-\u03b2-Smad signaling and renal fibrogenesis. J Am Soc Nephrol. 2016;27:3117\u201328.","journal-title":"J Am Soc Nephrol"},{"key":"1321_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrgastro.2017.35","volume":"14","author":"H Thomas","year":"2017","unstructured":"Thomas H. NAFLD: a critical role for the NLRP3 inflammasome in NASH. Nat Rev Gastroenterol Hepatol. 2017;14:197.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1321_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6489012","author":"XY Wan","year":"2016","unstructured":"Wan XY, Xu CF, Yu CH, Li YM. Role of NLRP3 inflammasome in the progression of NAFLD to NASH. Can J Gastroenterol Hepatol. 2016. https:\/\/doi.org\/10.1155\/2016\/6489012.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1321_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1344971","author":"RR Yan","year":"2024","unstructured":"Yan RR, Cai H, Zhou XF, Bao GD, Bai ZZ, Ge RL. Hypoxia-inducible factor-2\u03b1 promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells. Front Endocrinol. 2024. https:\/\/doi.org\/10.3389\/fendo.2024.1344971.","journal-title":"Front Endocrinol"},{"key":"1321_CR39","doi-asserted-by":"publisher","first-page":"154466","DOI":"10.1016\/j.phymed.2022.154466","volume":"107","author":"T Yang","year":"2022","unstructured":"Yang T, Wu E, Zhu X, Leng Y, Ye S, Dong R, et al. TKF, a mexicanolide-type limonoid derivative, suppressed hepatic stellate cells activation and liver fibrosis through inhibition of the YAP\/Notch3 pathway. Phytomedicine. 2022;107:154466.","journal-title":"Phytomedicine"},{"key":"1321_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jep.2015.08.034","volume":"175","author":"XY You","year":"2015","unstructured":"You XY, Xue Q, Fang Y, Liu QY, Zhang CF, Zhao C, et al. Preventive effects of Ecliptae Herba extract and its component, ecliptasaponin A, on bleomycin-induced pulmonary fibrosis in mice. J Ethnopharmacol. 2015;175:172\u201380.","journal-title":"J Ethnopharmacol"},{"key":"1321_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153270","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Wei MJ, Zhang SB, Huang ZL, Lu B, Ji LL. The water extract of Sophorae tonkinensis Radix et Rhizoma alleviates non- alcoholic fatty liver disease and its mechanism. Phytomedicine. 2020. https:\/\/doi.org\/10.1016\/j.phymed.2020.153270.","journal-title":"Phytomedicine"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01321-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01321-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01321-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:17:36Z","timestamp":1768342656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-025-01321-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1321"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01321-9","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}